Navigation Links
Risk of cancer in HIV patients reduced

It is a well known that HIV patients are at an increased risk of developing several different types of cancer. Now, a new study shows // aggressive antiretroviral therapy may help lower that risk. It was found that the use of highly active antiretroviral therapy was associated with a lower incidence of Kaposi sarcoma and non-Hodgkin's lymphoma.

The study was conducted on more than 7,300 patients infected with HIV and the data compared. Patients in the study had an increased risk of developing several different kinds of cancer, including anal cancer, non-Hodgkin's lymphoma, Kaposi sarcoma, Hodgkin's lymphoma, cervical cancer, liver cancer, cancer of the lip, mouth and pharynx, and non-melanoma skin cancer. It was also suggested that cutting down on smoking could also reduce the risk of other types of cancer associated with HIV infection.
'"/>




Page: 1

Related medicine news :

1. Vitamin B12 can help in detecting cancers
2. Want skin cancer? Please have a cigarette
3. New hope for cancer victims – will vaccine cure the deadly bug
4. Clintons new problem - Is the outgoing American president suffering from skin cancer?
5. Are cancer patients being taken for a ride?
6. Breast cancer treatment to be determined by gene test
7. Ductal lavage may detect early breast cancer
8. Beware of the oral patch! It could be cancer!!!
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Lose stomach for Life....Preventive removal of stomach saves the risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Risk cancer HIV patients reduced

Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 1ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 2ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 4Mount Sinai leads unprecedented NIH supported attempt to discover rules for assembling human tissue 58221 1Mount Sinai leads unprecedented NIH supported attempt to discover rules for assembling human tissue 58221 2Mount Sinai leads unprecedented NIH supported attempt to discover rules for assembling human tissue 58221 3Groundbreaking model of heart disease rewarded with NIH Pioneer Award 10079 1Groundbreaking model of heart disease rewarded with NIH Pioneer Award 10079 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 10079 3